501 related articles for article (PubMed ID: 23644232)
21. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
22. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract][Full Text] [Related]
23. Role of mTOR inhibitors in epilepsy treatment.
Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
[TBL] [Abstract][Full Text] [Related]
24. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
Tee AR; Sampson JR; Pal DK; Bateman JM
Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
[TBL] [Abstract][Full Text] [Related]
25. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
Aronica E; Specchio N; Luinenburg MJ; Curatolo P
Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
[TBL] [Abstract][Full Text] [Related]
26. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
Galanopoulou AS; Gorter JA; Cepeda C
Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin: one drug, many effects.
Li J; Kim SG; Blenis J
Cell Metab; 2014 Mar; 19(3):373-9. PubMed ID: 24508508
[TBL] [Abstract][Full Text] [Related]
28. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.
Huang X; Zhang H; Yang J; Wu J; McMahon J; Lin Y; Cao Z; Gruenthal M; Huang Y
Neurobiol Dis; 2010 Oct; 40(1):193-9. PubMed ID: 20566381
[TBL] [Abstract][Full Text] [Related]
30. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.
Anderl S; Freeland M; Kwiatkowski DJ; Goto J
Hum Mol Genet; 2011 Dec; 20(23):4597-604. PubMed ID: 21890496
[TBL] [Abstract][Full Text] [Related]
32. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
33. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
34. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
Jeong A; Wong M
Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
[TBL] [Abstract][Full Text] [Related]
35. Molecular therapies for tuberous sclerosis and neurofibromatosis.
Franz DN; Weiss BD
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
[TBL] [Abstract][Full Text] [Related]
36. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.
Kaur A; Sharma S
Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246
[TBL] [Abstract][Full Text] [Related]
37. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
38. The mTOR signalling cascade: paving new roads to cure neurological disease.
Crino PB
Nat Rev Neurol; 2016 Jul; 12(7):379-92. PubMed ID: 27340022
[TBL] [Abstract][Full Text] [Related]
39. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
[TBL] [Abstract][Full Text] [Related]
40. mTOR dysregulation and tuberous sclerosis-related epilepsy.
Curatolo P; Moavero R; van Scheppingen J; Aronica E
Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
